{"url_path":"/sec/txg/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1770787/0001628280-26-032388-index.html","accession_number":"0001628280-26-032388","cik":"0001770787","ticker":"TXG","issuer_name":"10x Genomics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1770787/0001628280-26-032388-index.html","primary_entity_key":"0001770787","primary_entity_name":"10x Genomics, Inc."},"word_count":1283,"has_tables":true,"body_markdown":"txg-20260331\nfalse2026Q112-310001770787one474xbrli:sharesiso4217:USDiso4217:USDxbrli:sharestxg:segmentxbrli:puretxg:patentClaimtxg:lawsuit00017707872026-01-012026-03-310001770787us-gaap:CommonClassAMember2026-04-300001770787us-gaap:CommonClassBMember2026-04-3000017707872026-03-3100017707872025-12-310001770787txg:ProductAndServiceRevenueMember2026-01-012026-03-310001770787txg:ProductAndServiceRevenueMember2025-01-012025-03-310001770787txg:LicensingAndRoyaltyRevenueMember2026-01-012026-03-310001770787txg:LicensingAndRoyaltyRevenueMember2025-01-012025-03-3100017707872025-01-012025-03-310001770787us-gaap:CommonStockMember2025-12-310001770787us-gaap:AdditionalPaidInCapitalMember2025-12-310001770787us-gaap:RetainedEarningsMember2025-12-310001770787us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-310001770787us-gaap:CommonClassAMemberus-gaap:CommonStockMember2026-01-012026-03-310001770787us-gaap:CommonClassAMemberus-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001770787us-gaap:CommonClassAMember2026-01-012026-03-310001770787us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001770787us-gaap:RetainedEarningsMember2026-01-012026-03-310001770787us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-03-310001770787us-gaap:CommonStockMember2026-03-310001770787us-gaap:AdditionalPaidInCapitalMember2026-03-310001770787us-gaap:RetainedEarningsMember2026-03-310001770787us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-310001770787us-gaap:CommonStockMember2024-12-310001770787us-gaap:AdditionalPaidInCapitalMember2024-12-310001770787us-gaap:RetainedEarningsMember2024-12-310001770787us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-3100017707872024-12-310001770787us-gaap:CommonClassAMemberus-gaap:CommonStockMember2025-01-012025-03-310001770787us-gaap:CommonClassAMemberus-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001770787us-gaap:CommonClassAMember2025-01-012025-03-310001770787us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001770787us-gaap:RetainedEarningsMember2025-01-012025-03-310001770787us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310001770787us-gaap:CommonStockMember2025-03-310001770787us-gaap:AdditionalPaidInCapitalMember2025-03-310001770787us-gaap:RetainedEarningsMember2025-03-310001770787us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-3100017707872025-03-310001770787us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2026-03-310001770787us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2025-12-310001770787us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2026-03-310001770787us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2025-12-310001770787us-gaap:BuildingMember2026-03-310001770787us-gaap:BuildingMember2025-12-310001770787us-gaap:LeaseholdImprovementsMember2026-03-310001770787us-gaap:LeaseholdImprovementsMember2025-12-310001770787us-gaap:MachineryAndEquipmentMember2026-03-310001770787us-gaap:MachineryAndEquipmentMember2025-12-310001770787us-gaap:LandMember2026-03-310001770787us-gaap:LandMember2025-12-310001770787us-gaap:ComputerEquipmentMember2026-03-310001770787us-gaap:ComputerEquipmentMember2025-12-310001770787us-gaap:FurnitureAndFixturesMember2026-03-310001770787us-gaap:FurnitureAndFixturesMember2025-12-310001770787us-gaap:ConstructionInProgressMember2026-03-310001770787us-gaap:ConstructionInProgressMember2025-12-310001770787us-gaap:DevelopedTechnologyRightsMember2026-03-310001770787us-gaap:DevelopedTechnologyRightsMember2025-12-310001770787txg:TechnologyLicensesMember2026-03-310001770787txg:TechnologyLicensesMember2025-12-310001770787txg:AssembledWorkforceMember2026-03-310001770787txg:AssembledWorkforceMember2025-12-310001770787us-gaap:CustomerRelationshipsMember2026-03-310001770787us-gaap:CustomerRelationshipsMember2025-12-310001770787txg:ScaleBioScienceInc.AcquisitionMember2026-01-012026-03-310001770787txg:ScaleBioScienceInc.AcquisitionMemberus-gaap:CommonClassAMember2026-01-012026-03-310001770787txg:ScaleBioScienceInc.AcquisitionMember2025-12-310001770787txg:ContingentConsiderationMembertxg:ScaleBioScienceInc.AcquisitionMember2026-01-012026-03-310001770787txg:AssumedLiabilitiesMembertxg:ScaleBioScienceInc.AcquisitionMember2026-01-012026-03-310001770787txg:ScaleBioScienceInc.AcquisitionMember2026-03-310001770787txg:ProductsAndServicesExcludingGrantRevenueMember2026-04-012026-03-3100017707872026-04-012026-03-310001770787txg:ChromiumInstrumentsMember2026-01-012026-03-310001770787txg:ChromiumInstrumentsMember2025-01-012025-03-310001770787txg:SpatialInstrumentsMember2026-01-012026-03-310001770787txg:SpatialInstrumentsMember2025-01-012025-03-310001770787txg:InstrumentsMember2026-01-012026-03-310001770787txg:InstrumentsMember2025-01-012025-03-310001770787txg:ChromiumConsumablesMember2026-01-012026-03-310001770787txg:ChromiumConsumablesMember2025-01-012025-03-310001770787txg:SpatialConsumablesMember2026-01-012026-03-310001770787txg:SpatialConsumablesMember2025-01-012025-03-310001770787txg:ConsumablesMember2026-01-012026-03-310001770787txg:ConsumablesMember2025-01-012025-03-310001770787us-gaap:ServiceMember2026-01-012026-03-310001770787us-gaap:ServiceMember2025-01-012025-03-310001770787country:US2026-01-012026-03-310001770787country:US2025-01-012025-03-310001770787txg:AmericasExcludingUnitedStatesMember2026-01-012026-03-310001770787txg:AmericasExcludingUnitedStatesMember2025-01-012025-03-310001770787srt:AmericasMember2026-01-012026-03-310001770787srt:AmericasMember2025-01-012025-03-310001770787us-gaap:EMEAMember2026-01-012026-03-310001770787us-gaap:EMEAMember2025-01-012025-03-310001770787country:CN2026-01-012026-03-310001770787country:CN2025-01-012025-03-310001770787txg:AsiaPacificExcludingChinaMember2026-01-012026-03-310001770787txg:AsiaPacificExcludingChinaMember2025-01-012025-03-310001770787srt:AsiaPacificMember2026-01-012026-03-310001770787srt:AsiaPacificMember2025-01-012025-03-310001770787txg:VizgenInc.Membertxg:LicensingAndRoyaltyRevenueMember2025-01-012025-03-310001770787us-gaap:PositiveOutcomeOfLitigationMembertxg:CurioPatentClaimsMember2024-03-252024-03-250001770787us-gaap:PositiveOutcomeOfLitigationMembertxg:IlluminaLawsuitsMember2025-10-012025-10-310001770787us-gaap:CommonClassAMember2026-03-310001770787us-gaap:CommonClassBMember2026-03-310001770787us-gaap:CostOfSalesMember2026-01-012026-03-310001770787us-gaap:CostOfSalesMember2025-01-012025-03-310001770787us-gaap:ResearchAndDevelopmentExpenseMember2026-01-012026-03-310001770787us-gaap:ResearchAndDevelopmentExpenseMember2025-01-012025-03-310001770787us-gaap:SellingGeneralAndAdministrativeExpensesMember2026-01-012026-03-310001770787us-gaap:SellingGeneralAndAdministrativeExpensesMember2025-01-012025-03-310001770787txg:TwoThousandsNineteenPlanMemberus-gaap:PerformanceSharesMember2026-02-012026-02-280001770787txg:CompoundAnnualGrowthRateMember2026-01-012026-03-310001770787srt:MinimumMembertxg:CompoundAnnualGrowthRateMember2026-01-012026-03-310001770787srt:MaximumMembertxg:CompoundAnnualGrowthRateMember2026-01-012026-03-310001770787txg:TotalShareholderReturnMember2026-01-012026-03-310001770787srt:MinimumMembertxg:TotalShareholderReturnMember2026-01-012026-03-310001770787srt:MaximumMembertxg:TotalShareholderReturnMember2026-01-012026-03-310001770787txg:MarketBasedPerformanceAwardsMembertxg:CompoundAnnualGrowthRateMember2026-01-012026-03-310001770787txg:MarketBasedPerformanceAwardsMembertxg:TotalShareholderReturnMember2026-01-012026-03-310001770787us-gaap:PerformanceSharesMember2026-01-012026-03-310001770787txg:TwoThousandsNineteenPlanMemberus-gaap:PerformanceSharesMember2025-03-012025-03-310001770787us-gaap:EmployeeStockMemberus-gaap:CommonClassAMembertxg:TwoThousandsNineteenEmployeeStockPurchasePlanMember2026-03-310001770787us-gaap:EmployeeStockMemberus-gaap:CommonClassAMembertxg:TwoThousandsNineteenPlanMember2026-01-012026-03-310001770787us-gaap:EmployeeStockMemberus-gaap:CommonClassAMembertxg:TwoThousandsNineteenEmployeeStockPurchasePlanMember2026-01-012026-03-310001770787us-gaap:EmployeeStockMemberus-gaap:CommonClassAMembertxg:TwoThousandsNineteenEmployeeStockPurchasePlanMember2025-01-012025-03-310001770787txg:TwoThousandsNineteenEmployeeStockPurchasePlanMemberus-gaap:EmployeeStockMember2026-03-310001770787us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001770787us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-03-310001770787txg:StockOptionsRestrictedStockAndEmployeeStockPurchasePlanMember2026-01-012026-03-310001770787txg:StockOptionsRestrictedStockAndEmployeeStockPurchasePlanMember2025-01-012025-03-310001770787txg:SharesUnderEsppPlanMember2026-01-012026-03-310001770787txg:SharesUnderEsppPlanMember2025-01-012025-03-310001770787txg:ShehnaazSulimanMember2026-01-012026-03-310001770787txg:SarahTeichmannMember2026-01-012026-03-310001770787txg:SarahTeichmannMember2026-03-31\n\n[Table of Contents](#id818e5dd412c4c208ac607748dd7528f_7)\n\nUNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWashington, D.C. 20549\n\n_____________________\n\nFORM 10-Q\n\n_____________________\n\n(Mark One)\n\n☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\nFor the quarterly period ended March 31, 2026\n\nOR\n\n☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\nFor the transition period from ___________ to ___________\n\nCommission File Number: 001-39035\n\n10x Genomics, Inc.\n\n(Exact name of registrant as specified in its charter)\n\nDelaware45-5614458\n\n(State or other jurisdiction of\nincorporation or organization)(I.R.S. Employer\nIdentification No.)\n\n6230 Stoneridge Mall Road\n\nPleasanton, California\n\n94588\n\n(Address of principal executive offices)\n(Zip Code)\n\n(925) 401-7300\n\n(Registrant’s telephone number, including area code)\n\nN/A\n\n(Former name, former address and former fiscal year, if changed since last report)\n\n_____________________\n\nSecurities registered pursuant to Section 12(b) of the Act:\n\nTitle of each classTrading\nSymbolName of each exchange\non which registered\n\nClass A common stock, par value $0.00001 per shareTXGThe Nasdaq Stock Market LLC\n\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes  ☒    No  ☐\n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐\n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\nLarge accelerated filer☒Accelerated filer☐\n\nNon-accelerated filer☐Smaller reporting company☐\n\nEmerging growth company☐\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐\n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  ☐   No  ☒\n\nAs of April 30, 2026, the registrant had 116,877,317 shares of Class A common stock, $0.00001 par value per share, outstanding and 10,078,872 shares of Class B common stock, $0.00001 par value per share, outstanding.\n\n[Table of Contents](#id818e5dd412c4c208ac607748dd7528f_7)\n\nTable of Contents\n\nPage\n\n[PART I.](#id818e5dd412c4c208ac607748dd7528f_13)\n\n[FINANCIAL INFORMATION](#id818e5dd412c4c208ac607748dd7528f_13)\n\n[Item 1.](#id818e5dd412c4c208ac607748dd7528f_16)\n\n[Financial Statements (Unaudited)](#id818e5dd412c4c208ac607748dd7528f_16)\n\n[3](#id818e5dd412c4c208ac607748dd7528f_16)\n\n[Condensed Consolidated Balance Sheets](#id818e5dd412c4c208ac607748dd7528f_19)\n\n[3](#id818e5dd412c4c208ac607748dd7528f_19)\n\n[Condensed Consolidated Statements of Operations](#id818e5dd412c4c208ac607748dd7528f_22)\n\n[4](#id818e5dd412c4c208ac607748dd7528f_22)\n\n[Condensed Consolidated Statements of Comprehensive Loss](#id818e5dd412c4c208ac607748dd7528f_25)\n\n[5](#id818e5dd412c4c208ac607748dd7528f_25)\n\n[Condensed Consolidated Statements of Stockholders’ Equity](#id818e5dd412c4c208ac607748dd7528f_28)\n\n[6](#id818e5dd412c4c208ac607748dd7528f_28)\n\n[Condensed Consolidated Statements of Cash Flows](#id818e5dd412c4c208ac607748dd7528f_31)\n\n[7](#id818e5dd412c4c208ac607748dd7528f_31)\n\n[Notes to Condensed Consolidated Financial Statements](#id818e5dd412c4c208ac607748dd7528f_34)\n\n[8](#id818e5dd412c4c208ac607748dd7528f_34)\n\n[Item 2.](#id818e5dd412c4c208ac607748dd7528f_67)\n\n[Management’s Discussion and Analysis of Financial Condition and Results of Operations](#id818e5dd412c4c208ac607748dd7528f_67)\n\n[17](#id818e5dd412c4c208ac607748dd7528f_67)\n\n[Item 3.](#id818e5dd412c4c208ac607748dd7528f_82)\n\n[Quantitative and Qualitative Disclosures about Market Risk](#id818e5dd412c4c208ac607748dd7528f_82)\n\n[21](#id818e5dd412c4c208ac607748dd7528f_82)\n\n[Item 4.](#id818e5dd412c4c208ac607748dd7528f_85)\n\n[Controls and Procedures](#id818e5dd412c4c208ac607748dd7528f_85)\n\n[21](#id818e5dd412c4c208ac607748dd7528f_85)\n\n[PART II.](#id818e5dd412c4c208ac607748dd7528f_88)\n\n[OTHER INFORMATION](#id818e5dd412c4c208ac607748dd7528f_88)\n\n[22](#id818e5dd412c4c208ac607748dd7528f_88)\n\n[Item 1.](#id818e5dd412c4c208ac607748dd7528f_91)\n\n[Legal Proceedings](#id818e5dd412c4c208ac607748dd7528f_91)\n\n[22](#id818e5dd412c4c208ac607748dd7528f_91)\n\n[Item 1A.](#id818e5dd412c4c208ac607748dd7528f_94)\n\n[Risk Factors](#id818e5dd412c4c208ac607748dd7528f_94)\n\n[22](#id818e5dd412c4c208ac607748dd7528f_94)\n\n[Item 2.](#id818e5dd412c4c208ac607748dd7528f_97)\n\n[Unregistered Sales of Equity Securities and Use of Proceeds](#id818e5dd412c4c208ac607748dd7528f_97)\n\n[22](#id818e5dd412c4c208ac607748dd7528f_97)\n\n[Item 5.](#id818e5dd412c4c208ac607748dd7528f_100)\n\n[Other Information](#id818e5dd412c4c208ac607748dd7528f_100)\n\n[22](#id818e5dd412c4c208ac607748dd7528f_100)\n\n[Item 6.](#id818e5dd412c4c208ac607748dd7528f_106)\n\n[Exhibits](#id818e5dd412c4c208ac607748dd7528f_106)\n\n[23](#id818e5dd412c4c208ac607748dd7528f_106)\n\n[Signatures](#id818e5dd412c4c208ac607748dd7528f_109)\n\n[24](#id818e5dd412c4c208ac607748dd7528f_109)\n\n[Table of Contents](#id818e5dd412c4c208ac607748dd7528f_7)\n\n10x Genomics, Inc.\n\nSPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS\n\nThis Quarterly Report on Form 10-Q (this “Quarterly Report”) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are subject to those sections’ “safe harbor.” All statements, other than historical facts, may be forward-looking statements. Forward-looking terminology such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “see,” “estimate,” “predict,” “potential,” “would,” “likely,” “seek” or “continue” or variations of these terms or similar terminology generally can identify forward-looking statements, but the absence of these words is not determinative. These forward-looking statements include statements regarding 10x Genomics, Inc.’s expectations regarding our plans, objectives, goals, beliefs, business strategies, acquisition of Scale Biosciences, Inc., results of operations, financial position, sufficiency of our capital resources, business outlook, future events, business conditions, key business metrics and key factors affecting our performance, revenues, gross margin, expenses, organization, business and other trends, expected future investments including anticipated capital expenditures, anticipated size of market opportunities and our ability to capture them, expected uses, plans and expectations regarding entering the clinical and diagnostic markets, the timing and outcome of regulatory filings and approvals, performance and benefits of our products and services, business trends and other information. These statements are based on management’s expectations, forecasts, beliefs, opinions, assumptions and information available at the time of filing and should not be relied upon as 10x Genomics, Inc.’s views as of any subsequent date. Actual outcomes and results could differ materially from these statements due to several factors. 10x Genomics, Inc. disclaims any obligation to update any published forward-looking statements except as required by law.\n\nThe material risks, uncertainties and other factors that could affect 10x Genomics, Inc.’s financial and operating results and cause actual results to differ from those indicated by the forward-looking statements made include those described in the section titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this Quarterly Report and Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025. Our periodic filings are accessible on the U.S. Securities and Exchange Commission's (“SEC”) website at www.sec.gov. Although we believe the expectations reflected in the forward-looking statements are reasonable, new risks and uncertainties may emerge, and it is not possible for us to predict their impact on the forward-looking statements contained in this Quarterly Report. Moreover, the information the forward-looking statements are based upon may be limited or incomplete, and may not be based upon all potentially relevant information. We cannot guarantee future events, circumstances, results, performance or achievements. In light of the foregoing, investors are urged not to place undue reliance on any forward-looking statement or third-party data in reaching any conclusion or making any investment decision about any securities of the Company.\n\nUnless otherwise stated or the context otherwise indicates, references to “we,” “us,” “our,” “the Company,” “10x” and similar references refer to 10x Genomics, Inc. and its subsidiaries.\n\n1\n\n[Table of Contents](#id818e5dd412c4c208ac607748dd7528f_7)\n\nChannels for Disclosure of Information\n\nInvestors and others should note that we may announce material information to the public through filings with the SEC, our website (https://www.10xGenomics.com), press releases, public conference calls, public webcasts and our social media accounts (https://www.linkedin.com/company/10xgenomics, https://X.com/10xGenomics, https://www.facebook.com/10xGenomics, https://bsky.app/profile/10xgenomics.bsky.social and https://www.youtube.com/@10xGenomics_). We use these channels to communicate with our customers and the public about the Company, our products, our services, our financial results, business developments and other matters. We encourage our investors, the media and others to review the information disclosed through such channels as such information could be deemed to be material information. The information on such channels, including on our website and our social media accounts, is not incorporated by reference in this Quarterly Report and shall not be deemed to be incorporated by reference into any other filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing. Please note that this list of disclosure channels may be updated from time to time.\n\n2\n\n[Table of Contents](#id818e5dd412c4c208ac607748dd7528f_7)\n\n10x Genomics, Inc.\n\nPART I—FINANCIAL INFORMATION"}